medigraphic.com

2013, Número S1

<< Anterior Siguiente >>

Rev Mex Anest 2013; 36 (S1)


Manejo anestésico para cirugía vascular

Brito-Guraieb G

Idioma: Español
Referencias bibliográficas: 57
Paginas: 194-198
Archivo PDF: 105.88 Kb.


FRAGMENTO

Se ha reportado que la incidencia de hemorragia subaracnoidea por aneurismas (HSAA) oscila de dos a 16 casos por cada 100,000 habitantes; existen variaciones regionales y étnicas; la frecuencia más alta se ha reportado en Finlandia con 22.5 casos por 100,000 habitantes y la menor en China con 2.2 casos por 100,000; se considera que en Centro y Sudamérica existe una baja incidencia. Cuando se comparan los aspectos económicos se demuestra que la incidencia casi se duplica en los países con bajos y medianos ingresos en relación con los países económicamente desarrollados.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Ingall T, Asplund K, Mahonen M, Bonita R. A multinational comparison of subarachnoid hemorrhage epidemiology in the WHO MONICA stroke study. Stroke. 2000;31:1054-1061.

  2. Feigin VL, Lawes CM, Bennett DA, Barker-Collo SL, Parag V. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurol. 2009;8:355–369.

  3. Schievink WI, Wijdicks EF, Parisi JE, Piepgras DG, Whisnant JP. Sudden death from aneurysmal subarachnoid hemorrhage. Neurology. 1995;45:871-874.

  4. de Rooij NK, Linn FH, van der Plas JA, Algra A, Rinkel GJ. Incidence of subarachnoid haemorrhage: a systematic review with emphasis on region, age, gender and time trends. J Neurol Neurosurg Psychiatry. 2007;78:1365-1372.

  5. Mayberg MR, Batjer HH, Dacey R, Diringer M, Haley EC, Heros RC, Sternau LL, Torner J, Adams HP Jr, Feinberg W, Thies W. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Circulation. 1994;90:2592-2605.

  6. Aoki T, Nishimura M. Targeting chronic inflammation in cerebral aneurysms: focusing on NF-kappaB as a putative target of medical therapy. Expert Opin Ther Targets. 2010;14:265-273.

  7. Aoki T, Kataoka H, Ishibashi R, Nozaki K, Hashimoto N. Simvastatin suppresses the progression of experimentally induced cerebral aneurysms in rats. Stroke. 2008;39:1276-1285.

  8. Larsson SC, Männistö S, Virtanen MJ, Kontto J, Albanes D, Virtamo J. Dietary fiber and fiber-rich food intake in relation to risk of stroke in male smokers. Eur J Clin Nutr. 2009;63:1016-1024.

  9. Larsson SC, Männistö S, Virtanen MJ, Kontto J, Albanes D, Virtamo J. Coffee and tea consumption and risk of stroke subtypes in male smokers. Stroke. 2008;39:1681-1687.

  10. Nieuwkamp DJ, Setz LE, Algra A, Linn FH, de Rooij NK, Rinkel GJ. Changes in case fatality of aneurysmal subarachnoid haemorrhage over time, according to age, sex, and region: a meta-analysis. Lancet Neurol. 2009;8(7):635-642.

  11. Samra SK, Giordani B, Caveney AF, Clarke WR, Scott PA, Anderson S, et al. Recovery of cognitive function after surgery for aneurysmal subarachnoid hemorrhage. Stroke. 2007;38:1864-1872.

  12. Al-Khindi T, Macdonald RL, Schweizer TA. Cognitive and functional outcome after aneurysmal subarachnoid hemorrhage. Stroke. 2010;41:e519-e536.

  13. Kassell NF, Torner JC, Haley EC Jr, Jane JA, Adams HP, Kongable GL. The International Cooperative Study on the Timing of Aneurysm Surgery. Part 1: overall management results. J Neurosurg. 1990;73:18-36.

  14. Bassi P, Bandera R, Loiero M, Tognoni G, Mangoni A. Warning signs in subarachnoid hemorrhage: a cooperative study. Acta Neurol Scand. 1991;84:277-281.

  15. Matsuda M, Watanabe K, Saito A, Matsumura K, Ichikawa M. Circumstances, activities, and events precipitating aneurysmal subarachnoid hemorrhage. J Stroke Cerebrovasc Dis. 2007;16:25-29.

  16. Fontanarosa PB. Recognition of subarachnoid hemorrhage. Ann Emerg Med. 1989;18:1199-1205.

  17. Ohman J. Hypertens as a risk factor for epilepsy after aneurismal subarachnoid hemorrhage and surgery. Neurosurgery. 1990;27:578-581.

  18. Connolly ES, Mayer SA. Initial misdiagnosis and outcome after subarachnoid hemorrhage. JAMA. 2004;291:866-869.

  19. Edlow JA. Diagnosing headache in the emergency department: what is more important? Being right, or not being wrong? Eur J Neurol. 2008;15:1257-1258.

  20. Diringer MN, Bleck TP, Claude HJ 3rd, Menon D, Shutter L, Vespa P, et al. Critical care management of patients following aneurysmal subarachnoid hemorrhage: recommendations from the neurocritical Care Society’s Multidisciplinary Consensus. Neurocrit Care. 2011;15:211-240.

  21. Con Fujii Y, Takeuchi S, Sasaki O, Minakawa T, Koike T, Tanaka R. Ultra-early rebleeding in spontaneous subarachnoid hemorrhage. J Neurosurg. 1996;84:35-42.

  22. Muench E, Horn P, Bauhuf C, et al. Effects of hypervolemia and hypertension on regional cerebral blood flow, intracranial pressure, and brain tissue oxygenation after subarachnoid hemorrhage. Crit Care Med. 2007;35:1844-1851.

  23. Nakatsuka M, Mizuno S, Uchida A. Extravasation on three dimensional CT angiography in patients with acute subarachnoid hemorrhage and ruptured aneurysm. Neuroradiology. 2002;44(1):25-30.

  24. Egge A, Waterloo K, Sjoholm H, Solberg T, Ingebrigtsen T, Romner B. Prophylactic hyperdynamic postoperative fluid therapy after aneurysmal subarachnoid hemorrhage: a clinical, prospective, randomized, controlled study. Neurosurgery. 2001;49.

  25. Kassell NF, Peerless SJ, Durward QJ, Beck DW, Drake CG, Adams HP. Treatment of ischemic deficits from vasospasm with intravascular volume expansion and induced arterial hypertension. Neurosurgery. 1982;11:337-343.

  26. Darby JM, Yonas H, Marks EC, Durham S, Snyder RW, Nemoto EM. Acute cerebral blood flow response to dopamine induced hypertension after subarachnoid hemorrhage. J Neurosurg. 1994;80:857-864.

  27. Miller JA, Dacey RG Jr, Diringer MN. Safety of hypertensive hypervolemic therapy with phenylephrine in the treatment of delayed ischemic deficits after subarachnoid hemorrhage. Stroke. 1995;26:2260-2266.

  28. Fraticelli AT, Cholley BP, Losser MR, Saint Maurice JP, Payen D. Milrinone for the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Stroke. 2008;39:893-898.

  29. Kramer AH, Zygun DA, Bleck TP, Dumont AS, Kassell NF, Nathan B. Relationship between hemoglobin concentrations and outcomes across subgroups of patients with aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2009;10:157-65.

  30. Hravnak M, Frangiskakis JM, Crago EA, et al. Elevated cardiac troponin I and relationship to persistence of electrocardiographic and echocardiographic abnormalities after aneurysmal subarachnoid hemorrhage. Stroke. 2009;40:3478-3484.

  31. Wartenberg KE, Schmidt JM, Claassen J, et al. Impact of medical complications on outcome after subarachnoid hemorrhage. Crit Care Med. 2006;34:617-623.

  32. Banki N, Kopelnik A, Tung P, et al. Prospective analysis of prevalence, distribution, and rate of recovery of left ventricular systolic dysfunction in patients with subarachnoid hemorrhage. J Neurosurg. 2006;105:15-20.

  33. Lee VH, Oh JK, Mulvagh SL, Wijdicks EF. Mechanisms in neurogenic stress cardiomyopathy after aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2006;5:243-249.

  34. Sampson TR, Dhar R, Diringer MN. Factors associated with the development of anemia after subarachnoid hemorrhage. Neurocrit Care. 2010;12:4-9.

  35. Dhar R, Zazulia AR, Videen TO, Zipfel GJ, Derdeyn CP, Diringer MN. Red blood cell transfusion increases cerebral oxygen delivery in anemic patients with subarachnoid hemorrhage. Stroke. 2009;40:3039-3044.

  36. Pasternak JJ, McGregor DG, Schroeder DR, Lanier WL, Shi Q, Hindman BJ, Clarke WR, et al; IHAST Investigators. Hyperglycemia in patients undergoing cerebral aneurysm surgery: its association with long-term gross neurologic and neuropsychological function. Mayo Clin Proc. 2008;83:406-417.

  37. Naidech AM, Levasseur K, Liebling S, et al. Moderate hypoglycemia is associated with vasospasm, cerebral infarction, and 3-month disability after subarachnoid hemorrhage. Neurocrit Care. 2010;12:181-187.

  38. Helbok R, Schmidt JM, Kurtz P, et al. Systemic glucose and brain energy metabolism after subarachnoid hemorrhage. Neurocrit Care. 2010;12:317-323.

  39. Schlenk F, Graetz D, Nagel A, Schmidt M, Sarrafzadeh AS. Insulin-related decrease in cerebral glucose despite normoglycemia in aneurysmal subarachnoid hemorrhage. Crit Care. 2008;12:R9.

  40. Fernandez A, Schmidt JM, Claassen J, et al. Fever after subarachnoid hemorrhage: risk factors and impact on outcome. Neurology. 2007;68:1013-1019.

  41. Rabinstein AA, Sandhu K. Non-infectious fever in the neurological Intensive Care Unit: incidence, causes and predictors. J Neurol Neurosurg Psychiatry. 2007;78:1278-1280.

  42. Oddo M, Frangos S, Milby A, et al. Induced normothermia attenuates cerebral metabolic distress in patients with aneurysmal subarachnoid hemorrhage and refractory fever. Stroke. 2009;40:1913-1916.

  43. Diringer MN. Treatment of fever in the neurologic Intensive Care Unit with a catheter-based heat exchange system. Crit Care Med. 2004;32:559-564.

  44. McCulloch TJ, Visco E, Lam AM. Graded hypercapnia and cerebral autoregulation during sevoflurane or propofol anesthesia. Anesthesiology. 2000;93(5):1205-1209.

  45. Nussmeier NA, Arlund C, Slogoff S. Neuropsychiatric complications after cardiopulmonary bypass: cerebral protection by a barbiturate. Anesthesiology. 1986;64:165-170.

  46. Pittman JE, Sheng H, Pearlstein R, Brinkhouse A, Dexter F, Warner DS. Comparison of the effects of propofol and pentobarbital on neurologic outcome and cerebral infarct size after temporary focal ischemia in the rat. Anesthesiology. 1997;87:1139-1144.

  47. Strebel S, Lam AM, Matta B, Mayberg TS, Aaslid R, Newell DW. Dynamic and static cerebral autoregulation during isoflurane, desflurane, and propofol anesthesia. Anesthesiology. 1995;83:66-76.

  48. Hemmings HC Jr, Mantz J. Xenon and the pharmacology of fear. Anesthesiology. 2008;109:954-955.

  49. Banks P, Franks NP, Dickinson R. Competitive Inhibition at the glycine site of the N-methyl-D-aspartate receptor mediates xenon neuroprotection against hypoxia-ischemia. Anesthesiology. 2010;112:614-622.

  50. Chiodini FC, Tassonyi E, FuchsγBuder T, Fathi M, Bertrand D, Muller D. Effects of neuromuscular blocking agents on excitatory transmission and γ-aminobutyric acid-A-mediated inhibition in the rat hippocampal slice. Anesthesiology. 1998;88:1003-1013.

  51. Matteo RS, Pua EK, Khambatta HJ, Spector S. Cerebrospinal fluid levels of d-tubocurarine in man. Anesthesiology. 1977; 46:396-9.

  52. Eddleston JM, Harper NJN, Pollard BJ, Edwards D, Gwinnutt CL. Concentrations of atracurium and laudanosine in cerebrospinal fluid and plasma during intracranial surgery. Br J Anaesth. 1989;63:525-530.

  53. Miller RD. Muscle relaxants in the ICU. ASA 1994 Annual Refresher Course Lectures, San Francisco. 1994;255-273.

  54. Szenohradszky J, Trevor AJ, Bickler P, Caldwell JE, Sharma ML, Rampil IJ, et al. Central nervous system effects of intrathecal muscle relaxants in rats. Anesth Analg. 1993;76:1304-1309.

  55. Cardone C, Szenohradszky J, Yost S, Bickler PE. Activation of brain acetylcholine receptors by neuromuscular blocking drugs. Anesthesiology. 1994;80:1155-1161.

  56. Curley G, Kavanagh BP, Laffey JG. Hypocapnia and the injured brain: more harm than benefit. Crit Care Med. 2010;38:1348-1359.

  57. Rozet I, Tontisirin N, Muangman S, Vavilala MS, Souter MJ, Lee LA, et al. Effect of equiosmolar solutions of mannitol versus hypertonic saline on intraoperative brain relaxation and electrolyte balance. Anesthesiology 2007;107:697-704.




2020     |     www.medigraphic.com